Skip to main content
. Author manuscript; available in PMC: 2022 Jan 24.
Published in final edited form as: Exp Neurol. 2020 Sep 17;334:113465. doi: 10.1016/j.expneurol.2020.113465

Table 4.

Contingency tables showing the proportion of experimental animals that responded to ampakine CX717 or HPCD with an acute increase in phrenic bursting. This was defined as an increase in the amplitude of the integrated phrenic inspiratory burst that was at least 10% above the baseline (pre-infusion) values. The CX717 group includes all animals that received CX717 (e.g., n=8 ampakine and n=8 ampakine + hypoxia). For the latter group, data were evaluated immediately prior to the hypoxia exposure. P-values represent the results of Fisher’s exact test of proportions in small sample sizes.

Phrenic Treatment Time Increase (n) No Change (n) P-value
Ipsilateral CX717 2 week 16 0 <0.001
HPCD 2 week 0 8
CX717 8 week 15 1 <0.001
HPCD 8 week 0 8
Contralateral CX717 2 week 15 1 <0.001
HPCD 2 week 0 8
CX717 8 week 15 1 <0.001
HPCD 8 week 0 8